 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Drug Information Specialist, Department of Pharmacy Services, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals and Physicians, Richmond, VA
Director, Drug Information Service, Department of Pharmacy Services, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals and Physicians
Reprints: Lynn Limon PharmD, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals and Physicians, 401 N. 12th St., B306, PO Box 980042, Richmond, VA 23298-0042, FAX 804/225-3919, E-mail llimon{at}hsc.vcu.edu
OBJECTIVE: To review information on desloratadine, a nonsedating antihistamine.
DATA SOURCES: An English-language MEDLINE search was conducted (1966–July 2002). References of identified articles were subsequently reviewed for additional data. Schering Corporation provided unpublished information.
STUDY SELECTION/DATA EXTRACTION: Articles and abstracts pertaining to desloratadine were considered for inclusion, with emphasis on randomized, placebo-controlled, double-blind trials.
DATA SYNTHESIS: Desloratadine is approved for the
treatment of symptoms associated with seasonal allergic rhinitis (SAR),
perennial allergic rhinitis (PAR), and chronic idiopathic urticaria (CIU) in
patients aged 
12 years. In placebo-controlled trials, desloratadine
demonstrated superior efficacy as a once-daily treatment of SAR, PAR, and CIU.
Data suggest that desloratadine has antiinflammatory and decongestant
activity.
CONCLUSIONS: Desloratadine appears to be a "me-too" agent, with no major differences compared with other second-generation antihistamines.
Key Words: allergic rhinitis, desloratadine, urticaria
Published Online, January 9, 2003. www.theannals.com, DOI
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-03-004-H01
 |
 |
 |
 |
 |
 |
 |
